Research ArticleArticle
Clinical Pharmacokinetics, Metabolism, and Drug-Drug Interaction of Carfilzomib
Zhengping Wang, Jinfu Yang, Christopher Kirk, Ying Fang, Melissa Alsina, Ashraf Badros, Kyriakos Papadopoulos, Alvin Wong, Tina Woo, Darrin Bomba, Jin Li and Jeffrey R. Infante
Drug Metabolism and Disposition January 2013, 41 (1) 230-237; DOI: https://doi.org/10.1124/dmd.112.047662
Zhengping Wang
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
Jinfu Yang
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
Christopher Kirk
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
Ying Fang
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
Melissa Alsina
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
Ashraf Badros
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
Kyriakos Papadopoulos
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
Alvin Wong
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
Tina Woo
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
Darrin Bomba
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
Jin Li
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
Jeffrey R. Infante
Onyx Pharmaceuticals, South San Francisco, California (Z.W., J.Y., C.K., Y.F., A.W., T.W., D.B., J.L.); H. Lee Moffitt Cancer and Research Center, Tampa, Florida (M.A.); Greenebaum Cancer Center, University of Maryland, Baltimore, Maryland (A.B.); The START (South Texas Accelerated Research Therapeutics) Center for Cancer Care, San Antonio, Texas (K.P.); and Sarah Cannon Research Institute, Nashville, Tennessee (J.R.I.)
DMD articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleArticle
PK, Metabolism, and Drug-Drug Interaction of Carfilzomib
Zhengping Wang, Jinfu Yang, Christopher Kirk, Ying Fang, Melissa Alsina, Ashraf Badros, Kyriakos Papadopoulos, Alvin Wong, Tina Woo, Darrin Bomba, Jin Li and Jeffrey R. Infante
Drug Metabolism and Disposition January 1, 2013, 41 (1) 230-237; DOI: https://doi.org/10.1124/dmd.112.047662
Research ArticleArticle
PK, Metabolism, and Drug-Drug Interaction of Carfilzomib
Zhengping Wang, Jinfu Yang, Christopher Kirk, Ying Fang, Melissa Alsina, Ashraf Badros, Kyriakos Papadopoulos, Alvin Wong, Tina Woo, Darrin Bomba, Jin Li and Jeffrey R. Infante
Drug Metabolism and Disposition January 1, 2013, 41 (1) 230-237; DOI: https://doi.org/10.1124/dmd.112.047662
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement